CL2023002216A1 - Composición farmacéutica que comprende un derivado de difenilpirazina - Google Patents
Composición farmacéutica que comprende un derivado de difenilpirazinaInfo
- Publication number
- CL2023002216A1 CL2023002216A1 CL2023002216A CL2023002216A CL2023002216A1 CL 2023002216 A1 CL2023002216 A1 CL 2023002216A1 CL 2023002216 A CL2023002216 A CL 2023002216A CL 2023002216 A CL2023002216 A CL 2023002216A CL 2023002216 A1 CL2023002216 A1 CL 2023002216A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- diphenylpyrazine derivative
- diphenylpyrazine
- derivative
- diphenylpyrazin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- PTZIVVDMBCVSMR-UHFFFAOYSA-N 2,3-diphenylpyrazine Chemical class C1=CC=CC=C1C1=NC=CN=C1C1=CC=CC=C1 PTZIVVDMBCVSMR-UHFFFAOYSA-N 0.000 title 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- -1 propan-2-yl amino butoxy acetate Chemical compound 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con una composición farmacéutica que comprende calcio; 4-5,6-difenilpirazin-2-il propan-2-il amino butoxi acetato, en particular a inyectables de acción prolongada que comprenden el mismo, el uso de la composición farmacéutica para el tratamiento o prevención de enfermedades específicas, y un proceso para producirlo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2021052208 | 2021-01-29 | ||
EP2021082830 | 2021-11-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023002216A1 true CL2023002216A1 (es) | 2024-03-01 |
Family
ID=80445780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023002216A CL2023002216A1 (es) | 2021-01-29 | 2023-07-27 | Composición farmacéutica que comprende un derivado de difenilpirazina |
Country Status (12)
Country | Link |
---|---|
US (2) | US20240091223A1 (es) |
EP (1) | EP4284334A1 (es) |
JP (1) | JP2024508377A (es) |
KR (1) | KR20230137312A (es) |
AU (1) | AU2022214282A1 (es) |
CA (1) | CA3206133A1 (es) |
CL (1) | CL2023002216A1 (es) |
CO (1) | CO2023010010A2 (es) |
IL (1) | IL304525A (es) |
MX (1) | MX2023008923A (es) |
TW (1) | TW202239408A (es) |
WO (1) | WO2022162158A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023214059A1 (en) | 2022-05-06 | 2023-11-09 | Actelion Pharmaceuticals Ltd | Diphenylpyrazine compounds as prodrugs |
WO2023238952A1 (ja) * | 2022-06-10 | 2023-12-14 | 日本新薬株式会社 | 医薬組成物 |
WO2024133620A1 (en) | 2022-12-22 | 2024-06-27 | Actelion Pharmaceuticals Ltd | In vitro dissolution test |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
TWI316055B (es) | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
WO2005014030A1 (en) * | 2003-07-24 | 2005-02-17 | Lutz-Henning Block | Method for treating lung diseases associated with ventilation-perfusion mismatches |
BRPI0908491A2 (pt) | 2008-02-28 | 2015-08-11 | Nippon Shinyaku Co Ltd | Inibidor de fibrose |
WO2009154246A1 (ja) | 2008-06-19 | 2009-12-23 | 日本新薬株式会社 | ***不全治療剤 |
WO2009157397A1 (ja) | 2008-06-23 | 2009-12-30 | 日本新薬株式会社 | 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤 |
CA2728089C (en) | 2008-06-23 | 2017-04-11 | Nippon Shinyaku Co., Ltd. | Therapeutic agent for spinal canal stenosis |
SI2289518T1 (sl) | 2008-06-23 | 2017-02-28 | Nippon Shinyaku Co., Ltd. | Terapevtsko sredstvo za vnetno črevesno bolezen |
SG176915A1 (en) | 2009-06-26 | 2012-01-30 | Nippon Shinyaku Co Ltd | Crystals |
WO2011024874A1 (ja) | 2009-08-26 | 2011-03-03 | 日本新薬株式会社 | 塩基付加塩 |
WO2014069401A1 (ja) * | 2012-10-29 | 2014-05-08 | 株式会社カルディオ | 肺疾患特異的治療剤 |
JOP20190204A1 (ar) | 2017-03-08 | 2019-09-05 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على سيليكسيباغ |
EP3658134A4 (en) | 2017-07-24 | 2021-05-05 | Pharmosa Biopharm Inc. | LIPOSOME COMPOSITIONS CONTAINING LOW ACID MEDICINAL PRODUCTS AND USES THEREOF |
US20210113464A1 (en) | 2017-11-27 | 2021-04-22 | Osaka University | Disease-site-specific liposomal formulation |
JP7032732B2 (ja) | 2018-03-01 | 2022-03-09 | 国立大学法人 東京大学 | プラテンシマイシンの製造方法 |
WO2020249602A1 (en) * | 2019-06-11 | 2020-12-17 | Actelion Pharmaceuticals Ltd | Methods for treating pulmonary arterial hypertension |
EP4021896A4 (en) * | 2019-08-19 | 2023-08-23 | Nippon Shinyaku Co., Ltd. | SALT |
-
2022
- 2022-01-27 TW TW111103620A patent/TW202239408A/zh unknown
- 2022-01-28 MX MX2023008923A patent/MX2023008923A/es unknown
- 2022-01-28 AU AU2022214282A patent/AU2022214282A1/en active Pending
- 2022-01-28 JP JP2023546048A patent/JP2024508377A/ja active Pending
- 2022-01-28 CA CA3206133A patent/CA3206133A1/en active Pending
- 2022-01-28 US US18/261,923 patent/US20240091223A1/en active Pending
- 2022-01-28 EP EP22703336.2A patent/EP4284334A1/en active Pending
- 2022-01-28 WO PCT/EP2022/052073 patent/WO2022162158A1/en active Application Filing
- 2022-01-28 KR KR1020237024534A patent/KR20230137312A/ko unknown
-
2023
- 2023-07-17 IL IL304525A patent/IL304525A/en unknown
- 2023-07-27 CL CL2023002216A patent/CL2023002216A1/es unknown
- 2023-07-27 CO CONC2023/0010010A patent/CO2023010010A2/es unknown
-
2024
- 2024-02-07 US US18/435,817 patent/US20240216366A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022214282A1 (en) | 2023-08-10 |
MX2023008923A (es) | 2023-08-10 |
IL304525A (en) | 2023-09-01 |
EP4284334A1 (en) | 2023-12-06 |
KR20230137312A (ko) | 2023-10-04 |
JP2024508377A (ja) | 2024-02-27 |
WO2022162158A1 (en) | 2022-08-04 |
TW202239408A (zh) | 2022-10-16 |
CO2023010010A2 (es) | 2023-08-09 |
US20240216366A1 (en) | 2024-07-04 |
US20240091223A1 (en) | 2024-03-21 |
CA3206133A1 (en) | 2022-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023002216A1 (es) | Composición farmacéutica que comprende un derivado de difenilpirazina | |
BR112018005454A2 (pt) | administração de potencializadores de cftr deuterados | |
UY33479A (es) | Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento | |
AR050717A1 (es) | Composiciones farmaceuticas | |
BR112017005242A2 (pt) | composto, composição farmacêutica, e, composto para uso. | |
BR112017028616A2 (pt) | acentuador de inibidores de homólogo de zeste 2 | |
CL2011001363A1 (es) | Proceso para la preparacion de un compuesto derivado de etorfina; compuesto derivado de etorfina; composicion farmaceutica que lo comprende; uso del compuesto como analgesico en el tratamiento del dolor. | |
CL2018001161A1 (es) | Composición dermocosmética, proceso de producción de la composición tópica, método para el fortalecimiento de uñas frágiles y uso de la composición | |
ATE420089T1 (de) | Substituierte azachinazoline mit antiviraler wirkung | |
ECSP22050840A (es) | Nuevos compuestos farmac?uticos | |
UY37538A (es) | Amidas aromáticas de ácidos carboxílicos | |
CO2019007671A2 (es) | Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer | |
UY27733A1 (es) | Derivados de ciclopenteno. | |
MX2020003660A (es) | Derivados de acido gluconico para ser usados en el tratamiento y/o prevencion de infecciones microbianas. | |
CL2021001944A1 (es) | Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias | |
BR112022016405A2 (pt) | Forma cristalina de voxelotor, composição farmacêutica, método para tratamento, e, voxelotor para uso no tratamento | |
BR112017005241A2 (pt) | composto, e, composição farmacêutica. | |
JOP20220045A1 (ar) | تركيبة صيدلانية مائية من جسم مضاد ANTI-PD1 برولجوليماب prolgolimab واستخدامها | |
BR112021011368A2 (pt) | Cocristal de cetoprofeno, composições compreendendo o mesmo, processo para a sua produção e usos dos mesmos | |
CO2019000942A2 (es) | Composición y uso de un péptido | |
AR058282A1 (es) | Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer. | |
PA8579401A1 (es) | Derivados de 2,3-dihidro-isoindol-1-ona como inhibidores de mao-b | |
DOP2013000144A (es) | Combinacion y composicion para el tratamiento de obesidad | |
ECSP13012765A (es) | Combinación y composición para el tratamiento de obesidad | |
TR201717703A2 (tr) | Api̇ksaban formülasyonlari |